The global anti-acne cosmetics market is a dynamic and evolving landscape, heavily influenced by regulatory updates across various regions. These regulations aim to ensure the safety, efficacy, and proper labelling of these products, protecting consumers from potential harm and misleading claims.
KEY REGULATORY BODIES AND THEIR ROLES
United States (FDA - Food and Drug Administration): The FDA is the primary regulatory body for cosmetics in the US. They oversee the safety and labelling of cosmetic products, including those targeting acne.
- Over the Counter (OTC) Drugs: Anti-acne products are often classified as OTC drugs if they contain active ingredients like benzoyl peroxide, salicylic acid, or adapalene (a retinoid). These products are subject to stringent regulations, including pre-market approval based on monograph requirements.
- Cosmetics: Products claiming to reduce acne but without active drug ingredients (e.g., some cleansers or moisturizers) fall under cosmetic regulations. They must be safe for their intended use, properly labeled, and free from adulteration or misbranding.
- GMP (Good Manufacturing Practices): FDA enforces GMP for manufacturing facilities to ensure product quality and consistency.
European Union (EU - European Commission): The EU has a comprehensive regulatory framework for cosmetics under the Cosmetics Regulation (EC) No 1223/2009.
- Annexes: The Cosmetics Regulation includes annexes that detail permitted and prohibited substances, including restrictions on ingredients known to cause irritation or adverse reactions.
- Safety Assessment: Cosmetic products must undergo a safety assessment conducted by a qualified safety assessor before they can be placed on the market. This assesses the potential risks associated with the ingredients and the product's formulation.
- PIF (Product Information File): Manufacturers must maintain a Product Information File (PIF) containing detailed information about the product, including its formulation, manufacturing process, safety assessment, and labeling information.
- Notification via CPNP (Cosmetic Products Notification Portal): Manufacturers must notify the EU authorities via CPNP before placing their products on the market.
China (NMPA - National Medical Products Administration): China has a complex and evolving regulatory landscape.
- Classification: Anti-acne products are classified based on their ingredients and claimed effects. Products with specific claims or containing certain active ingredients might be categorized as special-purpose cosmetics or even drugs, requiring more rigorous testing and approval.
- Ingredient Restrictions: China has a list of permitted and prohibited ingredients, with strict limits on the use of certain substances.
- Animal Testing: While the trend is towards reducing animal testing, it's still required for some imported cosmetics, particularly those considered special-purpose cosmetics.
Japan (MHLW - Ministry of Health, Labour and Welfare): Japan's regulatory framework is based on the Pharmaceutical Affairs Law (PAL), which governs both pharmaceuticals and cosmetics.
- Quasi-Drugs (Medicated Cosmetics): Anti-acne products containing specific active ingredients (e.g., certain types of salicylic acid) are often classified as quasi-drugs, requiring pre-market approval and adherence to specific manufacturing standards.
- Ingredient Restrictions and Permitted Lists: Japan has lists of permitted and prohibited ingredients, with strict limits on the use of certain substances.
Other Regions: Similar regulatory bodies and frameworks exist in other regions like India (CDSCO - Central Drugs Standard Control Organization), Canada (Health Canada), Australia (TGA - Therapeutic Goods Administration), and various countries in Southeast Asia and Latin America. These regions often adopt regulations based on international standards or adapt them to their local needs.
KEY REGULATORY UPDATES
- The European Union updated its Cosmetics Regulation (EC) No 1223/2009 by revising the lists of prohibited and restricted substances In April 2024. Appendix II (Annex II, Regulation 1223/2009/EC on Cosmetic Products, as amended by Regulation (EU) 2024/996, OJ L of 4 April 2024) now includes additional substances that are prohibited from use in cosmetic products, ensuring higher safety standards. Meanwhile, Appendix III lists substances with restrictions on their concentration or specific usage conditions, allowing for controlled use in cosmetics. These revisions aim to enhance consumer safety, adapt to new scientific data, and align with international regulations. The updates underscore the EU’s commitment to rigorous safety assessments and transparent regulation of cosmetic ingredients, promoting safer products across the market.
- The Commission Delegated Regulation (EU) 2024/197, published on January 5, 2024, amends the CLP Regulation (Regulation (EU) No 1272/2008) by updating its harmonized classification and labeling provisions. This regulation introduces significant updates, including the addition of 28 new entries, modifications to 24 existing classifications, and the introduction of new hazard classifications for certain substances, notably those exhibiting endocrine-disrupting properties. These updates aim to enhance the clarity and consistency of chemical hazard communication across the EU. The new provisions will become effective on September 1, 2025, providing stakeholders adequate time to comply with the revised requirements.
- Modernization of Cosmetics Regulation Act of 2022: The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) expanded the United States Food and Drug Administration’s (FDA) capacity to ensure the safety of the beauty and cosmetic industry. It has been one of the most significant expansions of cosmetic regulation since 1938. The new regulation mandates that cosmetics sold in the United States adhere to several updated requirements, including the reporting of serious adverse events, compliance with Good Manufacturing Practices (GMPs), mandatory facility registration, and comprehensive product listing submissions.
- The Amendment of the Cosmetic Rules, 2020 in India aimed to strengthen regulations governing cosmetic products to ensure safety and quality. The amendments include updates to licensing procedures, manufacturing practices, and labelling requirements. They emphasize strict compliance with safety standards, monitoring of ingredients, and proper documentation. The rules also enhance the authority of regulatory agencies like the Central Drugs Standard Control Organization (CDSCO) to enforce compliance and take punitive actions against violations. These changes aim to protect consumers from substandard or harmful cosmetics, promote fair trade practices, and align Indian regulations with international standards, fostering a safer cosmetics industry in the country.
NMPA Notice No. 51 (2021), Technical Guideline on Cosmetic Safety Assessment in China provides comprehensive procedures for evaluating the safety of cosmetic products, including ingredient safety, toxicological testing, risk assessment, and labeling requirements. The guideline emphasizes a science-based approach, requiring manufacturers to conduct detailed safety evaluations before market approval. It aims to strengthen regulatory oversight, ensure consumer safety, and promote transparency in cosmetic safety management. The notice aligns with international standards and updates previous regulations to reflect advances in safety assessment methodologies, fostering a more robust regulatory framework for cosmetic products in China.